These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30842342)

  • 21. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
    Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
    J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
    Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
    Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
    Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC).
    Azad AK; Qiu X; Boyd K; Kuang Q; Emami M; Perera N; Palepu P; Patel D; Chen Z; Cheng D; Feld R; Leighl NB; Shepherd FA; Tsao MS; Xu W; Liu G; Cuffe S
    Lung Cancer; 2014 Jun; 84(3):289-94. PubMed ID: 24679952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
    Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
    Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
    J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
    Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
    Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
    Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
    Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
    Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
    Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer.
    Choi SH; Do SK; Lee SY; Choi JE; Kang HG; Hong MJ; Lee JH; Lee WK; Jeong JY; Shin KM; Do YW; Lee EB; Park JE; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2022 Dec; 13(23):3322-3330. PubMed ID: 36239337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Takeda M; Yamanaka T; Seto T; Hayashi H; Azuma K; Okada M; Sugawara S; Daga H; Hirashima T; Yonesaka K; Urata Y; Murakami H; Saito H; Kubo A; Sawa T; Miyahara E; Nogami N; Nakagawa K; Nakanishi Y; Okamoto I
    Cancer; 2016 Apr; 122(7):1050-9. PubMed ID: 26828788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.